Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. Which is the better fit depends on your goals.
| RXRX | VCIT | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $84.82 |
52-Week Low | $2.84 | $81.45 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
VCIT trades at $81.71, down 0.28% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.33-$0.34, reflecting its income-focused strategy. News coverage highlights VCIT's competitive expense ratio of 0.03% and yield advantages over peers like VGIT and IEI, though technical indicators suggest near-term pressure with support clustered around $82.
The outlook balances VCIT's low-cost access to intermediate-term corporate bonds against interest rate sensitivity and economic cycle risks. Current bearish momentum warrants caution, but the fund's structural efficiency and yield appeal position it for income investors seeking diversified credit exposure amid fluctuating fixed-income conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
